Sky Eclat
JF-Expert Member
- Oct 17, 2012
- 57,761
- 216,011
AstraZeneca's Tagrisso approved in EU in early lung cancer
AstraZeneca's Tagrisso approved in EU in early lung cancer
www.directorstalkinterviews.com
Mimi ninayo dawa ya kutibu Cancer ya Mapafu kwa stage zake zote 4.At the forefront of lung cancer treatment
To improve lung cancer outcomes, we are prioritising research, increasing early screening and diagnosis and addressing unmet needs at all disease stages.www.astrazeneca.com
Lung cancer is the leading cause of cancer death worldwide, accounting for about 2.2 million patients diagnosed and 1.8 million deaths each year.1 The two main types of lung cancer are non-small cell lung cancer (NSCLC), which represents 80-85% of patients, and small cell lung cancer (SCLC), the more aggressive and fast-growing cancer type representing about 15% of patients.2-3
The earlier we can detect and treat lung cancer, the closer we are to cure.4-5 Unfortunately, early diagnosis is not always a reality.6
In many cases, lung cancer goes undetected until it is in advanced stages or the cancer comes back after initial treatment.6 For these patients who experience recurrence, outcomes are especially poor.4-5 To meaningfully improve outcomes, we are prioritising lung cancer research to increase early screening and diagnosis and address the significant unmet need for treatments at every stage of the disease continuum.
Our portfolio of approved and potential new medicines in late-stage development spans different histologies, several stages of disease, lines of therapy and modes of action.7 Our approach is driven by precision medicine, using groundbreaking science to further our understanding of lung cancer and deliver medicines matched to the patients who can best benefit from them. This includes thinking differently about the underlying biology of lung cancer, from early stages – where we aim to help patients live longer and cancer-free – to late stages, where we look to meaningfully extend survival.
Targeting Biomarkers and Resistance Mechanisms
By focusing on the unique properties of a tumour and looking in new places – beyond traditional classifications – we are defining new biomarkers and therapeutic targets to transform the way people with lung cancer are diagnosed and treated.
Post nzima sikuona mahala paliposema kuwa chanjo ya covid inaweza kutibu cance ya mapafu. labda kama kuna mstari sijauona vizuri. Astrazaneca ni kampuni sio chanjo ya covid.Ni chanjo ya covid ambayo faida zake za ziada ni kutibu lung cancer
Tuandikie kwa lugha yetu adhimu ya kiswahiliAt the forefront of lung cancer treatment
To improve lung cancer outcomes, we are prioritising research, increasing early screening and diagnosis and addressing unmet needs at all disease stages.www.astrazeneca.com
Lung cancer is the leading cause of cancer death worldwide, accounting for about 2.2 million patients diagnosed and 1.8 million deaths each year.1 The two main types of lung cancer are non-small cell lung cancer (NSCLC), which represents 80-85% of patients, and small cell lung cancer (SCLC), the more aggressive and fast-growing cancer type representing about 15% of patients.2-3
The earlier we can detect and treat lung cancer, the closer we are to cure.4-5 Unfortunately, early diagnosis is not always a reality.6
In many cases, lung cancer goes undetected until it is in advanced stages or the cancer comes back after initial treatment.6 For these patients who experience recurrence, outcomes are especially poor.4-5 To meaningfully improve outcomes, we are prioritising lung cancer research to increase early screening and diagnosis and address the significant unmet need for treatments at every stage of the disease continuum.
Our portfolio of approved and potential new medicines in late-stage development spans different histologies, several stages of disease, lines of therapy and modes of action.7 Our approach is driven by precision medicine, using groundbreaking science to further our understanding of lung cancer and deliver medicines matched to the patients who can best benefit from them. This includes thinking differently about the underlying biology of lung cancer, from early stages – where we aim to help patients live longer and cancer-free – to late stages, where we look to meaningfully extend survival.
Targeting Biomarkers and Resistance Mechanisms
By focusing on the unique properties of a tumour and looking in new places – beyond traditional classifications – we are defining new biomarkers and therapeutic targets to transform the way people with lung cancer are diagnosed and treated.
Msukuma mpumbavu yeye chanjo haimhusu kwa sababu hana uwezo wa kusafiri njee ya nchi yeye biashara zake ni za hapahapa bongiMsukuma ameanza kuhoji msimamo wa maprofesa ambao mpaka March mwaka huu wakisema hakuna Covid Tanzania na sasa hivi wanahamasisha chanjo.
Msukuma mpumbavu yeye chanjo haimhusu kwa sababu hana uwezo wa kusafiri njee ya nchi yeye biashara zake ni za hapahapa bongi
Post nzima sikuona mahala paliposema kuwa chanjo ya covid inaweza kutibu cance ya mapafu. labda kama kuna mstari sijauona vizuri. Astrazaneca ni kampuni sio chanjo ya covid.
Astrazaneca sio chanjo ya Covid 19, hilo ni jina la kampuni, kama ukisikia kuna chanjo ya Johnson and Johnson, ni jina la kampuni.Oncology – AstraZeneca - Redefining Cancer Care
Our Oncology strategy is built with one goal in mind – to push the boundaries of science to transform the lives of patients living with cancer. Learn morewww.astrazeneca.com